Redwire Launches New Venture Company, SpaceMD, to Commercialize Pharmaceutical Development in Space; Signs Trailblazing Royalty Agreement with ExesaLibero Pharma
SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire's innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics.
As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis.
The results of these microgravity investigations will inform ExesaLibero Pharma's Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products.
'Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,' said Peter Cannito, Chairman and CEO of Redwire. 'This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.'
'We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,' said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. 'This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.'
Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire's microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes.
About Redwire
Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit RDW.com.
SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotech, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
3 hours ago
- Globe and Mail
Redwire Launches New Venture Company, SpaceMD, to Commercialize Pharmaceutical Development in Space; Signs Trailblazing Royalty Agreement with ExesaLibero Pharma
Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that it has formed a new entity, SpaceMD, which will focus on growing seed crystals in orbit that will be used on Earth to create new and reformulated pharmaceuticals. SpaceMD will take advantage of the unique microgravity environment in space through the use of Redwire's innovative and flight-proven Pharmaceutical In-Space Laboratory (PIL-BOX) technology to grow the seed crystals. 28 PIL-BOX systems have already flown in space and have successfully crystalized 17 compounds on the ISS, including insulin and other critical molecules. SpaceMD will sell or license these seed crystals to companies that can use them to create reformulated versions of existing drugs or entirely new therapeutics. As part of this launch, SpaceMD announced a trailblazing licensing agreement with ExesaLibero Pharma, Inc., an innovative pharmaceutical company developing new small molecule drugs to treat bone disease. Under the terms of the agreement, ExesaLibero Pharma will work with SpaceMD to advance and enhance its groundbreaking small-molecule drug ELP-004 and other relevant compounds via the PIL-BOX system. This drug could hold the key to controlling the insidious bone erosion that numerous debilitating diseases cause, such as rheumatoid arthritis, multiple myeloma, diabetes, periodontal disease, and tuberculosis. The results of these microgravity investigations will inform ExesaLibero Pharma's Investigative New Drug (IND) application to the Food and Drug Agency (FDA). Following the approval of the IND by the FDA, ExesaLibero Pharma expects to initiate clinical trials that will lead to full approval of the drug for clinical use. Through this first-of-its-kind agreement, SpaceMD will receive royalties from any commercial sales of resulting pharmaceutical products. 'Redwire is excited to announce the formation of SpaceMD. This new entity represents the evolution of our PIL-BOXstrategy, moving from experimentation to full commercialization with significant upstream revenue potential,' said Peter Cannito, Chairman and CEO of Redwire. 'This agreement with ExesaLibero Pharma signals a revolutionary paradigm shift for commercial utilization of microgravity. Redwire and now SpaceMD are translating the benefits of microgravity research into product value for pharmaceutical companies with the goal of transforming the future of therapeutics and creating value for our stakeholders.' 'We have seen firsthand how the microgravity environment can be a game-changer for drug development, and we look forward to expanding our work with SpaceMD through this exciting collaboration,' said John Barnett, Ph.D., President and Chief Scientific Officer at ExesaLibero. 'This collaboration will help us continue to advance our drug development and discovery process and lead to better outcomes for patients and future astronauts.' Redwire is a global leader in microgravity research and development technologies, having flown hundreds of experiments on both the Space Shuttle and the ISS. Redwire currently has eleven research and manufacturing facilities on the ISS, more than any other company in the world. Redwire's microgravity technology enables space biotechnology and pharmaceutical development, helping customers reach a commercial market and paving the way for microgravity research on future commercial space stations. Previous investigations conducted by Redwire have been with partners such as Bristol Myers Squibb, Eli Lilly and Company, and Butler University. These efforts focused on unlocking insights to improve treatments for cardiovascular disease, obesity, and diabetes. About Redwire Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems and multi-domain operations leveraging digital engineering and AI automation. Redwire's approximately 1,300 employees located throughout the United States and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit SpaceMD is a subsidiary of Redwire Corporation focused on leveraging the microgravity environment of space to create new advances in pharmaceuticals, biotech, and other fields. SpaceMD utilizes innovative, flight-proven Redwire hardware to conduct this potentially life-enhancing work. SpaceMD uses the unique nature of space to benefit life on Earth.
Globe and Mail
3 hours ago
- Globe and Mail
Is Costco Stock Still the Safest Bet? Data Backs the Defensive Case
At a time when volatility continues to haunt, Costco Wholesale Corporation COST remains a poster child for defensive investing. The company's unique membership-based model and pricing discipline have solidified its position as a resilient force in the retail space. A key indicator of this strength is the 90.2% global membership renewal rate, alongside a 5.2% increase in worldwide shopping traffic during the third quarter of fiscal 2025. Membership revenues continue to be a key pillar for Costco. In the third quarter, income from membership fees increased 10.4% year over year, providing a steady revenue stream in a volatile environment. Paid memberships grew 6.8% to 79.6 million, with renewal rates remaining steady at 92.7% in the United States and Canada. Executive memberships, which now account for 73.1% of total sales, demonstrate member loyalty. Costco's operational agility further bolsters its defensive profile. The company has effectively navigated tariff disruptions and supply-chain constraints by rerouting goods and sourcing more from local suppliers. This flexibility helps contain cost pressures and allows it to offer the best possible prices. For example, by manufacturing or procuring Kirkland Signature items within the countries where they are sold, Costco has reduced shipping expenses and improved price consistency. Kirkland Signature continues to gain traction, with its sales outpacing overall company growth and penetration up 50 basis points year over year. Additionally, initiatives like the 'Buy Now, Pay Later' option and e-commerce expansion reflect Costco's forward-thinking approach, strengthening its defensive appeal in an evolving retail landscape. Costco's Price Performance, Valuation and Estimates Costco, which competes with Dollar General Corporation DG and Target Corporation TGT, has been a standout performer, with shares rallying 18.8% in the past year, outpacing the industry 's growth of 11.9%. Shares of Dollar General and Target have declined 11.7% and 25.5%, respectively, in the aforementioned period. From a valuation standpoint, Costco's forward 12-month price-to-earnings ratio stands at 48.15, higher than the industry's ratio of 31.77. COST carries a Value Score of D. Costco is trading at a premium to Target (with a forward 12-month P/E ratio of 12.70) and Dollar General (17.85). The Zacks Consensus Estimate for Costco's current financial-year sales and earnings per share implies year-over-year growth of 8.1% and 11.6%, respectively. Costco currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Target Corporation (TGT): Free Stock Analysis Report Dollar General Corporation (DG): Free Stock Analysis Report
Globe and Mail
4 hours ago
- Globe and Mail
J&J Expects Better Top-Line Growth in 2H: Can It Achieve the Goal?
Johnson & Johnson JNJ announced strong second-quarter results earlier this month. The drug and medical device giant beat estimates for both earnings and sales. Despite the loss of exclusivity ('LOE') of its blockbuster drug, Stelara, its Innovative Medicine unit once again outperformed expectations, with sales of all key drugs Darzalex, Erleada and Tremfya beating estimates. The new drugs also contributed significantly to sales. Importantly, its MedTech sales improved from first-quarter levels, driven by strong momentum in Cardiovascular, Surgery and Vision segments despite continued headwinds in China. But what caught investor attention is the fact that J&J raised its sales expectations for 2025 by around $2.0 billion at the mid-point to reflect a strong operational performance in the first half, coupled with currency tailwinds. The sales guidance was raised from a range of $91.0 billion-$91.8 billion to $93.2 billion-$93.4 billion. The sales range indicates growth in the range of 5.1%-5.6% versus the prior expectation of 2.6%-3.6%. The adjusted earnings per share guidance was raised from a range of $10.50-$10.70 to $10.80-$10.90, driven by top-line strength, the favorable impact of foreign currency and lowered tariff impact. J&J halved its expectations for tariff-related costs this year from $400 million to $200 million. J&J expects operational sales growth in both the Innovative Medicine and MedTech segments to be higher in the second half than in the first. Newly launched products should drive better growth in the Innovative Medicine segment in the second half despite the impact of Stelara LOE and Medicare Part D redesign. The growth is expected to be driven by its key products, such as Darzalex, Tremfya, Spravato and Erleada as well as new drugs like Carvykti, Tecvayli and Talvey and new indications, including Tremfya in inflammatory bowel disease indications and Rybrevant in non-small cell lung cancer. In the MedTech segment, the increased adoption of newly launched products in Cardiovascular, Surgery and Vision is likely to drive growth. However, China will continue to be a headwind in 2025. Sales are expected to be higher in the second half than the first half as the business moves past tougher first-half comps and new products gain momentum throughout 2025. We believe that J&J should be able to maintain the strong momentum of the first half in the second half. In fact, J&J expects growth to accelerate from 2026. ABBV & BMY Also Raise Guidance Other drugmakers that also raised their financial outlook for the year, along with their second-quarter results, are AbbVie ABBV and Bristol-Myers BMY. ABBV raised its full-year 2025 EPS guidance to $11.88-$12.08, up from its prior $11.67-$11.87 range.' Bristol-Myers raised its annual revenue guidance to $46.5-$47.5 billion from $45.8-$46.8 billion. BMY, however, cut its EPS outlook due to IPRD charges related to its recent deal with BioNTech BNTX for the global co-development and co-commercialization of BNTX's investigational bispecific antibody BNT327 across numerous solid tumor types. JNJ's Price Performance, Valuation and Estimates J&J's shares have outperformed the industry year to date. The stock has risen 17.6% in the year-to-date period against a 3.3% decrease of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 15.0 forward earnings, slightly higher than 14.29 for the industry. The stock is, however, trading below its five-year mean of 15.68. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2025 earnings has risen from $10.62 per share to $10.86 over the past 30 days, while that for 2026 has risen from $11.0 to $11.36 over the same timeframe. Image Source: Zacks Investment Research J&J has a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Johnson & Johnson (JNJ): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
